Gene and cell therapy company Oxford Biomedica Plc said on Wednesday that it has expanded its strategic partnership with Bristol Myers Squibb, inking a new commercial supply agreement for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes.
Under the new agreement, Oxford Biomedica was expected to commence commercial manufacturing at its facilities in Oxford and Durham, North Carolina in 2026, subject to regulatory approval.
Oxford Biomedica expects the supply agreement to generate "meaningful multi-year revenue" and support existing medium-term financial guidance. It also noted that the expanded partnership builds on the pair's existing relationship, which was originally announced in March 2020.
As of 0815 GMT, Oxford Biomedica shares were up 1.83% at 833p.
Reporting by Iain Gilbert at Sharecast.com